Why This Study Matters
Postmastectomy radiation therapy (PMRT) improves local control and breast cancer survival. In the EBCTCG patient-level meta-analysis cited by the authors, PMRT decreased 10-year local recurrence from 20% to 4% (p<0.00001) and reduced 20-year breast cancer mortality from 50% to 42% (p=0.01) in patients with 1–3 positive lymph nodes.
Radiation is shifting toward shorter schedules (hypofractionation), supported by prospective trials after breast-conserving therapy. After mastectomy, however, most women in the United States are treated with breast reconstruction, and the authors note a reluctance to apply hypofractionation there because of concern about reconstruction complications. RT CHARM was designed to fill that evidence gap.
Study Design
RT CHARM (Radiation Therapy, Conventional vs. Hypofractionation, Accelerated, after Reconstruction and Mastectomy) was a two-arm, unblinded, non-inferiority trial run through the Alliance for Clinical Trials in Oncology, with assistance from the Canadian Cancer Trials Group and NRG Oncology investigators. The journal text does not state a trial phase; The ASCO Post describes it as a phase III, multicenter, open-label non-inferiority trial (external source: ascopost.com, October 2026). Patients were randomized 1:1 using a dynamic allocation algorithm, stratified by immediate vs delayed reconstruction and autologous vs implant-only reconstruction.
| Arm | Schedule |
|---|---|
| Conventional (control) | 50 Gy in 25 daily fractions |
| Hypofractionated (experimental) | 42.56 Gy in 16 daily fractions |
The primary endpoint was the proportion of patients with one or more ipsilateral reconstruction complications within 24 months after PMRT, a composite of unplanned readmission, reoperation, Baker grade III–IV capsular contracture, or total loss of the reconstructed breast. The trial assumed a 25% two-year complication rate with conventional PMRT and a 10% non-inferiority margin; 792 evaluable patients (396 per arm) gave 90% power at a one-sided type I error of 0.025.
898 patients enrolled (2018–2021); 825 evaluable (ITT), 403 conventional and 422 hypofractionated; 209 sites in the US and Canada; 1:1 randomization, unblinded; median follow-up 3.9 years (reverse Kaplan-Meier).
Patient Population
Eligible patients were 18 or older with ECOG performance status 0–1 and a completed mastectomy for invasive breast carcinoma (AJCC v8 T0N1–2a, T1N1–2a, T2N1–2a, or T3N0–2a, all M0) with completed, ongoing, or planned reconstruction. Patients with T4 or N3 disease, positive margins, active collagen vascular disease, synchronous bilateral or prior ipsilateral breast cancer, or prior thoracic RT were excluded. Median age was 49 years (range 24–79); 76% had N1 disease; 51% received neoadjuvant chemotherapy. By reconstruction strata, 219 (27%) were immediate and 474 (58%) delayed; 400 (49%) were implant-only and 293 (41%) autologous (with or without implant).
Primary Endpoint
The composite reconstruction complication rate at 24 months after radiation was 11.3% across all evaluable patients: 10.2% with conventional fractionation and 12.3% with hypofractionation, a difference of −2.1% (95% CI −6.5% to 2.2%), non-inferiority p = 0.0001. An analysis limited to patients who completed reconstruction within 18 months of radiation also showed non-inferiority: 10.4% vs 12.6%, difference −2.2% (95% CI −7.2% to 2.8%), p = 0.001. Across all patients, the individual components were 5.2% unplanned hospital admission, 7.8% unplanned reoperation, 3.6% Baker grade 3–4 capsular contracture, and 1.2% complete reconstruction failure.
A 16-fraction course of hypofractionated PMRT is non-inferior to conventional radiation in women undergoing breast reconstruction after mastectomy.
— RT CHARM conclusion, J Clin Oncol
Locoregional Control
Three-year local and locoregional recurrence-free survival was 96.2% (95% CI 94.3–98.2%) with conventional and 97.0% (95% CI 95.4–98.7%) with hypofractionated radiation (HR 1.01, 95% CI 0.53–1.96, p = 0.97). There were 8 recurrences in the conventional arm and 10 in the hypofractionated arm. Estimated 3-year cumulative incidence of local and locoregional recurrence was 2.2% (95% CI 1.1–4.3%) vs 1.5% (95% CI 0.7–3.2%).
Subgroup Analyses
The trial did not randomize by reconstruction type or timing. The authors report that results across six reconstruction subgroups did not appear to differ by radiation arm, but the groups became too small to declare statistical non-inferiority. Descriptive 24-month complication proportions (as treated, 631 patients who completed reconstruction within 18 months) are shown below; no subgroup hazard ratios or p-values were reported in this table.
| Reconstruction group | Conventional | Hypofractionated | Overall |
|---|---|---|---|
| Immediate TE & Delayed Implant | 15.4% (n = 91) | 19.3% (n = 109) | 17.5% (n = 200) |
| All Delayed Implant +/− TE | 10% (n = 10) | 18.8% (n = 16) | 15.4% (n = 26) |
| Immediate TE & Delayed Autologous +/− Implant | 13.8% (n = 58) | 13.8% (n = 58) | 13.8% (n = 116) |
| All Delayed Autologous +/− Implant +/− TE | 5.9% (n = 34) | 13.9% (n = 36) | 10% (n = 70) |
| Immediate Implant only | 8.3% (n = 72) | 5.3% (n = 75) | 6.8% (n = 147) |
| All Immediate Autologous +/− Implant | 0.0% (n = 33) | 2.6% (n = 39) | 1.4% (n = 72) |
In a pre-planned multivariable analysis of patients who completed reconstruction, treatment arm (OR 1.172, 95% CI 0.708–1.938, p = 0.537), body mass index, and history of diabetes were not significant predictors of complications. Delayed reconstruction carried higher odds than immediate reconstruction regardless of arm (OR 2.96, 95% CI 1.4–6.2, p = 0.004). Implant-only vs autologous reconstruction showed slightly increased odds that did not reach statistical significance (OR 1.65, 95% CI 1.0–2.8, p = 0.07).
Safety Profile
| Toxicity measure | Conventional | Hypofractionated | Comparison |
|---|---|---|---|
| Acute grade ≥3 non-reconstruction toxicity (any attribution) | 7.7% | 5.0% | 2.7% difference, 95% CI −0.6% to 6.0%, p = 0.11 |
| Acute dermatitis, grade 2 | 171 (42%) | 84 (20%) | p < .0001 |
| Acute dermatitis, grade 3 | 11 (3%) | 3 (1%) | p = 0.048 |
Toxicity attributed to radiation was otherwise low without an apparent difference between arms, per the authors. Radiation plan quality was rated per-protocol or acceptable in 805 (90%) of cases; 40 (4%) were unacceptable and 53 (6%) were not submitted for review.
Interpretation and Broader Context
The observed overall complication rate (11.3%) was well below the 25% assumed at design, which the authors acknowledge could invite criticism of the 10% margin. They note that the 95% confidence interval (−6.5%, 2.2%) would support non-inferiority for any margin of 6.5% or higher. The authors describe consistency with the FABREC randomized study (400 patients, implant-only reconstruction, overall complication rate of 9.8% at 15 months excluding capsular contracture) and a separate Chinese phase 3 trial that excluded reconstruction.
The authors conclude that, together with prior prospective evidence, the results support hypofractionated PMRT for the majority of patients who require PMRT, including those undergoing reconstruction, while urging caution for patients with T4 or N3 disease and for proton therapy, which were not studied. Patient-reported outcomes, photographic assessment, lymphedema analysis and an economic analysis will be reported separately.
Limitations
The trial was unblinded. It did not randomize by reconstruction type or timing, and the six reconstruction subgroups became too small to declare statistical non-inferiority within any of them. The observed overall complication rate (11.3%) was well below the 25% assumed when the 10% margin was set, which the authors acknowledge could invite criticism of that margin. Median follow-up was 3.9 years, so recurrence estimates are early. Patients with T4 or N3 disease and proton therapy were not studied, and patient-reported outcomes, photographic assessment, lymphedema and economic analyses are not yet reported.